Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

Mass General Brigham logo

Mass General Brigham

Status and phase

Completed
Phase 2

Conditions

Bipolar Disorder

Treatments

Dietary Supplement: cytidine
Drug: placebo
Dietary Supplement: omega-3 fatty acids

Study type

Interventional

Funder types

Other

Identifiers

NCT00854737
2009-P-000149

Details and patient eligibility

About

The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.

Full description

Previous studies examining the effect of omega-3 fatty acids on bipolar depression have had mixed results. Some studies have found that omega-3 fatty acids have a positive effect on bipolar depression symptoms, while other studies have found no difference between placebo and omega-3 fatty acid treatment. The variable effects noted with omega-3 fatty acids may be due in part to a real effect with limited potency. Larger effects might be achieved by combining agents with synergistic effects. Cytidine is necessary to form key intermediates in the biosynthesis of the phospholipids phosphatidylcholine and phosphatidylethanolamine, which are major components of eukaryotic cell membranes. Recent human studies by our group have shown that CDP-choline (a compound composed of cytidine and choline) can modify brain phospholipid synthesis in healthy adults and may have antidepressant effects (Babb et al., 1996; Babb et al., 2002; Carlezon et al., 2002; Renshaw et al., 1999). The combination of omega-fatty acids and the related pyrimidine, uridine, was associated with enhanced antidepressant-like activity in rats (Carlezon et al., 2005). Thus, the combination of omega-3 fatty acid and cytidine, which is interconverted with uridine in the body, may provide a safe and powerful way to treat bipolar disorder, especially bipolar depression. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.

Enrollment

90 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • bipolar disorder
  • mood episode within past year
  • stable medication regimen

Exclusion criteria

  • primary psychiatric disorder other than bipolar disorder
  • significant suicide or homicide risk
  • unstable medical conditions
  • current or planned pregnancy
  • lactose intolerance
  • medications affecting lipid absorption or metabolism
  • clozapine treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

90 participants in 3 patient groups, including a placebo group

1
Active Comparator group
Description:
Omega-3 fatty acid and cytidine supplementation
Treatment:
Dietary Supplement: omega-3 fatty acids
Dietary Supplement: cytidine
2
Active Comparator group
Description:
omega-3 fatty acid supplementation
Treatment:
Dietary Supplement: omega-3 fatty acids
placebo
Placebo Comparator group
Description:
placeno or sugar pill
Treatment:
Drug: placebo

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems